Person: İLHAN, MAHMUT MUZAFFER
25 results
Search Results
Now showing 1 - 10 of 25
Publication Metadata only Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?(2015-10-01) Ilhan, MAHMUT MUZAFFER; Kahraman, Ozlem Timirci; Turan, Saime; Turgut, SEDA; Karaman, Ozcan; Zeybek, Umit; SHUKUROV, Samir; Yaylim, Ilhan; Tasan, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; TURGUT, SEDA; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRULObjectives. - Genetic alterations explaining the clinical variability of prolactinomas still could not be clarified and dopamine D2 receptor (DRD2) polymorphism is a putative candidate for the variable response to dopaminergic treatment. The present study was conducted to investigate the influence of DRD2 TaqI A polymorphism on initial and follow-up characteristics of prolactinoma. Patients and methods. - Seventy-two patients with prolactinoma and 98 age and gender matched control subjects were recruited to the case-control study. Serum prolactin levels were assessed by enzyme-linked immunosorbent assay and DRD2 polymorphism was determined by polymerase chain reaction and restriction length polymorphism analysis. Results. - Decrease of prolactin levels and the tumor shrinkage after cabergoline treatment were 93.9 +/- 5.9% and 58.3 +/- 33.1% in microadenomas and 96.1 +/- 6.1% and 51.7 +/- 29.3 in macroadenomas (P = 0.02 and P > 0.05, respectively). We observed no significant difference for DRD2 genotypes and the alleles between the patients and healthy group (P > 0.05). Prolactin levels before treatment were correlated with tumor diameter before and after treatment and the percentage of prolactin decrease with treatment (P 0.05). Conclusion. - This study revealed that DRD2 TaqI A receptor polymorphism was not associated with the development of prolactinoma and its clinical characteristics. Future studies are needed to clarify the clinical implications of genetic alterations in prolactinoma. (C) 2015 Elsevier Masson SAS. All rights reserved.Publication Open Access Investigation of the Vitamin D Receptor Polymorphisms in Acromegaly Patients(2015-01-01) Ilhan, MAHMUT MUZAFFER; TOPTAS-HEKIMOGLU, Bahar; YAYLIM, Ilhan; Turgut, SEDA; TURAN, Saime; Karaman, Ozcan; Tasan, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; TURGUT, SEDA; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRULObjective. The genetic structural alterations in the majority of somatotroph adenomas are not clarified and the search for novel candidate genes is still a challenge.We aimed to investigate possible associations between vitamin D receptor (VDR) polymorphisms and acromegaly. Design, Patients, and Methods. 52 acromegaly patients (mean age 45.7 ± 1.9 years) and 83 controls (mean age 43.1 ± 2.6 years) were recruited to the study. VDR polymorphism was determined by polymerase chain reaction-based restriction fragment length polymorphism methods. Results. The distribution of VDR genotypes showed a significant difference in the frequencies of VDR FokI genotypes between patients and controls (𝑃 = 0.034). VDR FokI ff genotype was significantly decreased in acromegaly patients (𝑃 = 0.035) and carriers of FokI Ff genotype had a 1.5-fold increased risk for acromegaly (OR: 1.5, 95% CI: 1.07–2.1; 𝑃 = 0.020). IGF1 levels after treatment were significantly higher in patients carrying the Ff genotype compared to carrying ff genotype (𝑃 = 0.0049). 25(OH)D3 levels were significantly lower in acromegaly patients (𝑃 < 0.001). Conclusions. Our study suggests that VDR FokI genotypes might affect the development of acromegaly and VDR polymorphisms may play a role in the course of acromegaly as a consequence of altering hormonal status.Publication Metadata only A novel AVP gene mutation in a Turkish family with neurohypophyseal diabetes insipidus(2016-03-01) Ilhan, MAHMUT MUZAFFER; Tiryakioglu, N. O.; KARAMAN, O.; Coskunpinar, E.; YILDIZ, R. S.; TURGUT, SEDA; Tiryakioglu, D.; TOPRAK, HÜSEYİN; TASAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TURGUT, SEDA; TOPRAK, HÜSEYİN; TAŞAN, ERTUĞRULPurpose Familial neurohypophyseal diabetes insipidus (FNDI) is a rare, autosomal dominant, inherited disorder which is characterized by severe polydipsia and polyuria generally presenting in early childhood. In the present study, we aimed to analyze the AVP gene in a Turkish family with FNDI.Publication Open Access An Unusual Case of Cushing’s Syndrome: Coexistence of Functional Pituitary and Adrenal Adenoma(2017-04-01) İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; YASİN ÇETİN, AYŞE İREM; BÜYÜKBAŞLI, NUR; HAMDARD, JAMSHİD; TAŞAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRULA case of adrenocorticotropic hormone (ACTH)-independent Cushing's syndrome, which develops in the course of ACTH-dependent Cushing's disease, is presented in this report. A 47-year-old woman with a past history of surgery and gamma knife radiosurgery because of Cushing's disease was admitted to the endocrinology clinic with weight gain and unregulated blood glucose levels. Hypercortisolemia was still persisting and diagnostic work-up indicated ACTH-independent Cushing's syndrome. Along with the rare possibility of this coexistence, longstanding ACTH hypersecretion can play a role in functional transition of adrenal adenomas. Further studies are needed to clarify the underlying mechanisms.Publication Metadata only Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey(2015-01-01T00:00:00Z) Tasan, ERTUĞRUL; HANIMOGLU, Hakan; Turgut, SEDA; Ilhan, MAHMUT MUZAFFER; EVRAN, Sevket; KAYNAR, Mehmet Yasar; TAŞAN, ERTUĞRUL; TURGUT, SEDA; İLHAN, MAHMUT MUZAFFERGiant prolactinoma is a rare subset of macroadenomas. Limited studies demonstrated which therapy could be successfully used in the first-line therapy of giant prolactinoma. We presented a case with a 54x40x40 mm pituitary adenoma and optic chiasmatic compression with left sphenoid sinus invasion. The tumor caused a loss of visual field of the right side. Cabergoline treatment was started with dose of 1.5 mg/week. Fifteen days later, the clinical visual acuity examination showed a significant improvement in the patient with visual field defect. After the five years follow-up magnetic resonance imagining showed reduction of the adenoma size (17x12 mm) was significant. Our findings suggest that, cabergoline can be used as a first-line therapy in giant prolactinomas because tumoral shrinkage without a surgical procedure and rapid improvement in visual field defect is achieved with this medical treatment.Publication Open Access The use of complementary medicine in patients with diabetes(2016-05-01) İLHAN, MAHMUT MUZAFFER; DEMİR, BÜŞRA; YÜKSEL, SENA; AYDIN ÇATAKLI, SERRA; YILDIZ, RABİA SEVDA; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRULOBJECTIVE: Diabetes mellitus (DM) is a growing health problem with serious complications. The chronic and progressive nature of the disease often leads patients to use complementary and integrative medicine. The present study aimed to investigate the frequency of use of alternative medicine by patients with DM and the products used. METHODS: Between September 2014 and May 2015, 301 patients with DM were selected from Bezmialem Foundation University Hospital Diabetes Clinic to participate in the study. RESULTS: The results of the study indicate that 81 (26.9%) patients had tried alternative medicine, and 50 (16.6%) patients continued to use some form of alternative medicine product. A total of 43 (14.3%) patients used such products every day and 24 (8%) patients had used alternative medicine products for up to 6 months. Glycated hemoglobin (HbA1c) levels were significantly decreased in patients using alternative medicine products compared to the remainder of patients in the study (p=0.017). No other significant difference was found between the two groups. It was observed that among patients using alternative medicine products, only 10 (12%) had informed their physicians. CONCLUSION: This study indicated that patients with diabetes are very likely to use alternative medicine products. Additional studies are needed to further determine the efficacy of these products. Patients as well as health providers must be educated about complementary medicine and alternative products.Publication Open Access Radiation field size and dose determine oncologic outcome in esophageal cancer.(2016-10-13T00:00:00Z) GEMICI, C; YAPRAK, G; BATIREL, HF; ILHAN, MAHMUT MUZAFFER; Mayadagli, ALPASLAN; İLHAN, MAHMUT MUZAFFER; MAYADAĞLI, ALPASLANPublication Metadata only Cushing-s syndrome in obese patients with type 2 diabetes: A single center screening study(2017-03-01) Karaman, Ozcan; ZUHUR, Sayid Shafi; CIL, Esra; OZDERYA, Aysenur; OZTURK, Feyza Yener; Ilhan, Muzaffer; ALTUNTAS, Yuksel; KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFERThe frequency of Cushing-s syndrome (CS) in obese patients was not properly determined and the studies focused on the frequency of occult CS and the possible improvement of diabetes and obesity with treatment of CS are needed. In this study, we aimed to investigate the frequency of CS in obese patients with type 2 diabetes. The study enrolled with 200 obese (body mass index (BMI) > 30 kg/m(2)), type 2 diabetes patients between 2009 and 2011 in Sisli Etfal Training and Research Hospital, Turkey. Twenty-eight males and 172 females were recruited to the study. Mean age of the study group was 51.7 +/- 8.5. Nineteen patients (9.5 %) failed to suppress cortisol levels less than 1.8 mu g/dL after a 1-mg overnight dexamethasone suppression test (ODST) and these patients proceeded to have a 2-day 2-mg low-dose dexamethasone suppression test. After further screening, three (%1.5) patients were diagnosed with CS in our study. Among the three patients diagnosed with CS, the tumor was located in the pituitary gland in two patients. The present study revealed that the frequency of Cushing-s syndrome in obese and diabetic patients were 1.5 %, which was much higher than the general population. Occult CS should take into account as an exacerbating factor for diabetes and screening for CS should be considered in poorly controlled diabetic patients.Publication Metadata only Polycystic ovary syndrome is associated with P-wave prolongation and increased P-wave dispersion(2013-09-01) ERDOGAN, Ercan; AKKAYA, Mehmet; TURFAN, Murat; BATMAZ, Gonca; BACAKSIZ, AHMET; TASAL, Abdurrahman; Ilhan, Muzaffer; KUL, Seref; SONMEZ, Osman; VATANKULU, Mehmet Akif; Tasan, ERTUĞRUL; BACAKSIZ, AHMET; İLHAN, MAHMUT MUZAFFER; TAŞAN, ERTUĞRULPublication Metadata only Graves- ophthalmopathy: the role of diffusion-weighted imaging in detecting involvement of extraocular muscles in early period of disease(2015-03-01) KILICARSLAN, R.; Alkan, ALPAY; ILHAN, M. M.; YETIS, H.; ARALASMAK, AYŞE; TASAN, ERTUĞRUL; ALKAN, ALPAY; İLHAN, MAHMUT MUZAFFER; ARALAŞMAK, AYŞE; TAŞAN, ERTUĞRULObjective: To evaluate involvement of the extraocular muscle (EOM) using diffusion-weighted imaging (DWI), to determine whether there is correlation with conventional orbital MRI and apparent diffusion coefficient (ADC) values in patients with Graves- ophthalmopathy (GO).
- «
- 1 (current)
- 2
- 3
- »